Fingolimod in relapsing remitting multiple sclerosis: Indication of added benefit in certain patients

Based on new analyses conducted by the drug manufacturer, an advantage can be determined in two instead of only one patient group for the use of Fingolimod in relapsing remitting multiple sclerosis. There are now indications instead of a hint.

from Today's Healthcare News -- ScienceDaily http://ift.tt/1ezF5yY